Pecknold J, Wilson R, le Morvan P
Department of Psychiatry, McGill University, Montréal, Canada.
Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:57-67.
The purpose of this study was to evaluate the short, intermediate, and long-term (8 weeks) effectiveness, as well as the withdrawal effects of zopiclone 7.5 mg. Eleven chronic insomniacs participated in the study where both EEG sleep recordings and a subjective rating scale were used to evaluate drug effects. Zopiclone significantly decreased total wake time and nocturnal awakenings, and increased total sleep time and sleep efficiency. These effects were apparent from first treatment night and tolerance to the hypnotic effect did not develop over the 8 weeks of treatment. The subjective sleep questionnaire data showed significantly decreased sleep latency time but otherwise were consistent with the sleep laboratory findings. Zopiclone decreased the percentage of Stage 1 sleep but did not significantly alter the percentage of Stage 2 sleep, slow wave sleep or REM sleep. The withdrawal of zopiclone was associated with a return of sleep variables towards pre-treatment baseline values. Although 2 patients dropped out, 1 with a marked rebound insomnia and daytime anxiety during the first week of withdrawal, the other because of side-effects and poor hypnotic efficiency, no evidence of rebound insomnia was seen on the sleep EEG or subjective questionnaire data in the study population.
本研究的目的是评估7.5毫克佐匹克隆的短期、中期和长期(8周)疗效以及撤药效应。11名慢性失眠症患者参与了该研究,研究中使用脑电图睡眠记录和主观评分量表来评估药物效果。佐匹克隆显著减少了总觉醒时间和夜间觉醒次数,增加了总睡眠时间和睡眠效率。这些效果从首次治疗当晚就很明显,并且在8周的治疗过程中未产生对催眠效果的耐受性。主观睡眠问卷数据显示睡眠潜伏期显著缩短,但在其他方面与睡眠实验室的结果一致。佐匹克隆降低了1期睡眠的百分比,但未显著改变2期睡眠、慢波睡眠或快速眼动睡眠的百分比。佐匹克隆撤药后,睡眠变量恢复到治疗前的基线值。尽管有2名患者退出研究,1名在撤药第一周出现明显的反弹性失眠和日间焦虑,另1名因副作用和催眠效果不佳退出,但在研究人群的睡眠脑电图或主观问卷数据中未发现反弹性失眠的证据。